A Janesville-based company is building a fusion energy facility to produce critical medical isotopes. Earlier this year, SHINE Technologies secured a $263 million loan from the U.S. Department of Energy’s Office of Energy Dominance Financing to build a new production facility for molybdenum-99, or Mo-99. This isotope has many uses in nuclear medicine, a main one being the parent isotope for technetium-99m, which helps diagnose and determine the stage of cancers and heart disease.